Enlivex Therapeutics is expected to report a Q2 2026 loss of $0.31 per share on $0.00 in revenue, with the stock currently trading at $1.28 against an aggressive analyst price target of $46.50. Investors are primarily focused on clinical updates for its lead candidate, Allocetra, following the recent FDA RMAT designation granted for treating age-related knee osteoarthritis.
Beyond clinical milestones, the market is intensely watching the company’s unique Digital Asset Treasury strategy involving the Rain protocol, which has reportedly driven a massive increase in treasury net asset value. This earnings report follows a major $400 million private placement in July 2026, which significantly fortified the balance sheet ahead of Phase 2b trial expansions.